MAP2K7 and cancer: Finally, therapies that associate BRAF inhibitors with MEK inhibitors (dabrafenib with trametinib and vemurafenib with cobimetinib) are the current treatment strategies for BRAF-mutant advanced cancers, including melanoma [11,12].